Successful treatment of diffuse pulmonary lymphangiomatosis with bevacizumab.
Jurjan
J
Aman
Erik
E
Thunnissen
Marinus A
MA
Paul
Geerten P
GP
van Nieuw Amerongen
Anton
A
Vonk-Noordegraaf
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000151:congenital* / Q000188:drug therapy; D008200:Lymphangiectasis / Q000151:congenital* / Q000188:drug therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab